Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer

Condition

Breast

Cancer

1 June 2026

Published on 01 Sep 2023
Last Updated on 01 Jun 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Olaparib 100 mg and 150 mg tablets as adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. Maximum duration of treatment: 1 year.

Funding status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.

Clinical indication, subsidy class and MediShield Life claims eligibility for olaparib are provided in the Annex.

Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer (Updated 1 Jun 2026) [PDF, 266 KB]

PES Olaparib for BRCA-mutated HER2-negative early breast cancer (Updated 2 Jan 2024) [PDF, 93 KB]

Back to top